Drug Trial Radar · NCT00903422
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
May 14, 2009
Primary completion
Jun 26, 2012
Study completion Dec 5, 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of eltrombopag in the treatment of low platelet counts in adult subjects with advanced myelodysplastic syndrome (MDS), secondary acute myeloid leukemia after MDS (sAML/MDS), or de novo AML that are relapsed, refractory or ineligible to receive azacitidine, decitabine, intensive chemotherapy or autologous/allogeneic stem cell transplantation. This is a placebo-controlled study in which patients will receive study medication daily for 6 months, during which time the dose of study medication may be adjusted based upon individual platelet counts and bone marrow blast counts. All subjects will receive best standard of care (platelet transfusions, mild chemotherapy, cytokines, valproic acid, all-trans retinoic acid, ESAs or G-CSF) in addition to study medication. Subjects taking placebo may be allowed to crossover to eltrombopag treatment if a clinically and statistically significant improvement in bone marrow blast counts is seen in subjects treated with eltrombopag.
Conditions
- Myelodysplastic Syndrome
Interventions
eltrombopag olamineDrug
thrombopoietin receptor agonist
PlaceboOther
Placebo tablets with no active pharmaceutical ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability parameters including non-hematological laboratory Grade 3/Grade 4 toxicities, change in bone marrow blast counts from baseline and adverse events reporting.Time frame: Approximately 46 months
Locations
65 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Santa Monica, California
GSK Investigational Site
Stanford, California
GSK Investigational Site
Coral Springs, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Camden, New Jersey
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Houston, Texas
GSK Investigational Site
New Braunfels, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Arlington, Virginia
GSK Investigational Site
Fairfax, Virginia
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
Salvador, Estado de Bahia, Brazil
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
Koebenhavn Oe, Denmark
GSK Investigational Site
Odense C, Denmark
GSK Investigational Site
Bayonne, France
GSK Investigational Site
Besançon, France
GSK Investigational Site
Bobigny, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Toulouse, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Stuttgart, Baden-Wurttemberg, Germany
GSK Investigational Site
Ulm, Baden-Wurttemberg, Germany
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.